



Carrie S. Cox
Chairman of the Board
NewCo

Carrie S. Cox has been named Chairman of the Board of NewCo, a global biopharmaceutical leader in women's health formed in 2020 when it was spun off from Merck & Co., Inc., Kenilworth, NJ, USA.

Cox brings significant leadership experience as the former Chairman and Chief Executive Officer (CEO) of Humacyte, Inc., a premier biomedical engineering pioneer. She joined Humacyte in 2010, and served as Chairman and CEO until June 2018 and as Executive Chairman into 2019.

Prior to her time at Humacyte, she served as Executive Vice President (EVP) and President, Global Pharmaceuticals, Schering-Plough Corporation, from 2003 until its merger with Merck & Co., Inc., in 2009. In this role, she was responsible for the company's global prescription pharmaceutical business, which generated approximately \$16 billion in annual sales and a 5 year CAGR of 22 percent.

Before Schering-Plough, Cox served as President, Global Prescription Business, at Pharmacia Corporation and as Senior Vice President (SVP) of Global Business Management at Pharmacia & Upjohn (the predecessor company to Pharmacia), as well as Vice President (VP) of Women's Healthcare at Wyeth-Ayerst. Cox spent her early career at Sandoz pharmaceuticals, now Novartis, in a variety of commercial roles.

Cox currently serves on the Board of Directors for both Texas Instruments and Cardinal Health. She also serves as Chairman of electroCore, a neuroscience company, and Selecta Biosciences, a clinical-stage biotechnology company. Cox previously served on the Board of Celgene, as Lead Director for Texas Instruments, and as Chairman of both Array BioPharma and Prism Pharmaceuticals.

Among her notable accomplishments, Cox has been named 6 times to *FORTUNE Magazine's* list of the "50 Most Powerful Women in Business."

Her work has been featured in the *Harvard Business Review* and in *The New York Times* bestseller *The Profit Zone*.

She received her BS from Massachusetts College of Pharmacy in 1981 and was a registered pharmacist.

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through Merck's prescription medicines, vaccines, biologic therapies and animal health products, the company works with customers and operates in more than 140 countries to deliver innovative health solutions. Merck also demonstrates our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world — including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases, including HIV and Ebola. For more information, visit www.merck.com and connect with Merck on [Twitter](#), [Facebook](#), [YouTube](#) and [LinkedIn](#).